Inactive Instrument

Mylan Inc Stock Nasdaq

Equities

US6285301072

Pharmaceuticals

End-of-day quote Nasdaq
- USD - Intraday chart for Mylan Inc
Sales 2024 * 14.92B Sales 2025 * 14.66B Capitalization 13.38B
Net income 2024 * 1.81B Net income 2025 * 791M EV / Sales 2024 * 1.79 x
Net Debt 2024 * 13.36B Net Debt 2025 * 11.63B EV / Sales 2025 * 1.71 x
P/E ratio 2024 *
8.57 x
P/E ratio 2025 *
16 x
Employees -
Yield 2024 *
4.47%
Yield 2025 *
4.59%
Free-Float 96.36%
More Fundamentals * Assessed data
Managers TitleAgeSince
Chief Executive Officer 61 22-12-28
Chief Tech/Sci/R&D Officer - -
Chief Operating Officer - 20-11-15
Members of the board TitleAgeSince
Chairman 56 20-11-15
Director/Board Member 68 20-11-15
Director/Board Member 66 20-11-15
More insiders
Viatris Inc. is a global healthcare company. The Company's segments include Developed Markets, Greater China, JANZ, and Emerging Markets. The Developed Markets segment comprises its operations primarily in North America and Europe. The Greater China segment includes its operations in China, Taiwan and Hong Kong. The JANZ segment reflects its operations in Japan, Australia, and New Zealand. The Emerging Markets segment encompasses its presence in more than 125 countries with developing markets and emerging economies, including in Asia, Africa, Eastern Europe, Latin America, and the Middle East, as well as the Company’s ARV franchise. The Company’s portfolio comprises approved molecules across a range of key therapeutic areas, including globally recognized iconic and key brands and generics, including complex products. The Company operates manufacturing sites across worldwide that produce oral solid doses, injectables and complex dosage forms.
Calendar
Related indices
More about the company